Workflow
医美新材料
icon
Search documents
医美材料大战正式打响,谁能胜出?
3 6 Ke· 2025-06-09 01:04
Core Insights - The medical beauty materials market is entering a competitive phase in 2025, with significant approvals for new materials such as agarose and hydroxyapatite, indicating a growing diversity of products [1][10] - The approval of various injection fillers, including recombinant collagen and animal-derived collagen, highlights the rapid development and commercialization of medical beauty materials [1][4] - Investment in medical beauty materials companies has surged, with 12 companies securing funding in the first five months of 2025, reflecting strong interest from investors [4][5] Regulatory Approvals - Hydroxyapatite received two approvals in 2025, with the first compliant product for medical beauty injections approved in February [10] - Agarose also saw its first approval in January 2025, marking a significant milestone for this material in the domestic market [10] - Over 110 products for medical beauty injections have been approved in China, primarily classified as Class III medical devices [2][4] Market Dynamics - The competition for the first regulatory approval (Class III certificate) is intense, as it provides a significant market advantage [10][12] - Companies are increasingly focusing on developing new materials and applications, with many aiming to secure the first approval in various new material categories [11][12] - The market is characterized by a mix of established companies and startups, all vying for a share of the growing medical beauty sector [15][16] Investment Trends - Notable investments in medical beauty materials companies include significant funding rounds for firms like 聚源生物 and 未名拾光, indicating robust investor confidence [5][6] - The trend of startups receiving funding is expected to continue, as the demand for innovative medical beauty solutions grows [4][5] Product Development - Companies are exploring the combination of different materials to enhance product competitiveness, with a focus on safety and efficacy [14][15] - New materials such as PDRN, silk protein, and chitosan are being investigated for their applications in medical beauty and functional skincare [16][17] - The development of multi-indication products is becoming a strategic focus, with companies aiming to address various aesthetic needs [13][15] Future Outlook - The medical beauty market is anticipated to expand, driven by the introduction of new materials and innovative applications [16][17] - The interplay between medical beauty and skincare sectors is expected to create a positive feedback loop, enhancing market growth [16][17] - Ultimately, the success of new materials will depend on their clinical validation and real-world application, as safety and effectiveness remain paramount [16][17]
“一个真正的商战”,医美巨头华熙生物、巨子生物矛盾激化 “大嘴博士”回应巨子生物最新声明:不认同
Mei Ri Jing Ji Xin Wen· 2025-06-02 15:51
Core Viewpoint - The ongoing public dispute between Huaxi Biological and Juzhi Biological highlights the competitive tension in the aesthetic medicine industry, particularly regarding hyaluronic acid and recombinant collagen products [3][10]. Group 1: Company Statements - Huaxi Biological issued a statement on June 1, 2023, supporting beauty blogger Dr. Hao Yu, criticizing an unnamed company for using "internet water army" tactics and threatening to disclose testing results if issues are not addressed [3][4]. - Juzhi Biological responded later that day, accepting an apology from the testing agency used by Dr. Hao Yu but asserting that they would pursue legal action against those spreading false information [3][8]. - Dr. Hao Yu contested Juzhi Biological's claims, stating that the testing agency's statement did not include an apology and questioned why Juzhi had not released its own testing results after ten days [9][10]. Group 2: Market Dynamics - The dispute is rooted in a broader competition for market share between hyaluronic acid and recombinant collagen, with Huaxi Biological's performance declining alongside the perception of hyaluronic acid as "outdated" [10]. - Huaxi Biological's revenue from functional skincare products, which include recombinant collagen, has seen significant declines of 18.45% and 31.62% in 2023 and 2024, respectively, while Juzhi Biological's "Kefumei" brand has shown strong growth with revenues of 27.88 billion and 45.4 billion in the same years [11]. - The pricing landscape for aesthetic products indicates that domestic hyaluronic acid is positioned at the lower end of the market, with prices ranging from approximately 1,000 to 2,000 yuan per unit, while recombinant collagen is priced higher, around 3,000 yuan [13][14]. Group 3: Industry Trends - The aesthetic medicine market is experiencing a shift with the introduction of new injectable materials, which has led to a decrease in hyaluronic acid's market share from 42% in 2021 to an estimated 36% in 2024 [16]. - The emergence of new materials, such as hydroxyapatite and PDRN solutions, is expected to further challenge the dominance of hyaluronic acid, although its unique properties may still provide competitive advantages [16][17].
报名!医美新材料交流会:琼脂糖 & 羟基磷灰石
思宇MedTech· 2025-03-07 14:20
近年来,新型医美填充材料倍受市场关注。2025年初,琼脂糖、羟基磷灰石相关产品在 国内获批上市,引发了行业对于其技术特点、临床应用、安全性及未来趋势的广泛讨 论。 本次交流会将聚焦这两类材料的特性及应用,为医美行业从业者、投资人、临床医生及 学者提供一个开放讨论的平台,探讨其技术原理、适用场景、操作经验及发展趋势,并 邀请行业专家共同交流。 会议安排 时间: 2025年3月12日(周三)14:30-16:00 地点: 上海交通大学医学院 会议议程 1.介绍八大处整形医学验证中心服务介绍和年度活动计划。 2.主题分享:琼脂糖与羟基磷灰石的技术综述 分享人:思宇MedTech主编赵清 内容概览: #琼脂糖的技术特点 主要成分、凝胶特性及降解机制 与现有填充材料的对比(吸水性、塑形力、适用部位) 近期行业动态及市场趋势 #羟基磷灰石的技术特点 主要成分、刺激胶原增生的作用机制 适用于面部填充的优势与挑战 规模: 20~30人 对象: 医美行业从业者、投资人、临床医生、学者 医美行业对该成分的监管趋势 注:主题分享来自于文献资料的收集。欢迎相关企业代表参与讨论并分享更多观点。 3. 圆桌讨论 & 观点碰撞 琼脂糖 v ...
报名!医美新材料交流会:琼脂糖 & 羟基磷灰石
思宇MedTech· 2025-03-04 03:52
近年来,新型医美填充材料倍受市场关注。2025年初,琼脂糖、羟基磷灰石相关产品在 国内获批上市,引发了行业对于其技术特点、临床应用、安全性及未来趋势的广泛讨 论。 本次交流会将聚焦这两类材料的特性及应用,为医美行业从业者、投资人、临床医生及 学者提供一个开放讨论的平台,探讨其技术原理、适用场景、操作经验及发展趋势,并 邀请行业专家共同交流。 1.介绍八大处整形医学验证中心服务介绍和年度活动计划。 2.主题分享:琼脂糖与羟基磷灰石的技术综述 分享人:思宇MedTech主编赵清 内容概览: #琼脂糖的技术特点 主要成分、凝胶特性及降解机制 与现有填充材料的对比(吸水性、塑形力、适用部位) 会议安排 时间: 2025年3月12日(周三)14:30-16:00 地点: 上海交通大学医学院 会议议程 注:主题分享来自于文献资料的收集。欢迎相关企业代表参与讨论并分享更多观点。 3. 圆桌讨论 & 观点碰撞 琼脂糖 vs 透明质酸:临床应用上的优劣对比 羟基磷灰石的优势:刺激胶原增生是否带来长期效果? 两种材料的适用人群及部位探讨 医生的使用体验:注射技巧、并发症管理、患者反馈 市场趋势与投资机会:新材料是否会占据更多市场 ...